Trial Profile
A Phase II, Placebo-Controlled, Multicenter, Dynamic Randomized, Double Blind Trial of RC18, a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Inadequate Response of TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Telitacicept (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors RemeGen
- 01 Apr 2019 Status changed from recruiting to discontinued.
- 27 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 27 Aug 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.